Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOCTP.L Regulatory News (OCTP)

  • There is currently no data for OCTP

Total Voting Rights

28 May 2021 07:00

RNS Number : 8646Z
Oxford Cannabinoid Tech.Holdings
28 May 2021
 

Oxford Cannabinoid Technologies Holdings Plc 

 

Total Voting Rights

 

 

Oxford Cannabinoid Technologies Holdings Plc ("Company"), announces that, in accordance with FCA's Disclosure Guidance and Transparency Rules, as at 28 May 2021, the Company's issued share capital consists of 960,415,644 Ordinary Shares of £0.01, each with one voting right. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company is 960,415,644.

 

The above figure of 960,415,644 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

For more information:

 

The Company

Oxford Cannabinoid Technologies Holdings Plc

Dr John Lucas

+44 (0)7956 873125

 

The Financial Adviser

Cairn Financial Advisers LLP

Emily Staples or Jo Turner

+44 (0)20 7213 0897

or +44 (0)20 7213 0885

The Corporate Adviser

States Bridge Capital Ltd

Damion Carruel

+44 (0)7775516745

The PR Adviser

Acuitas Communications

Simon Nayyar or James Gittings

44 (0)20 3848 2815 or

+44 (0)20 3848 2812

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRPPUACAUPGUMQ
Date   Source Headline
6th Mar 202311:05 amRNSSecond Price Monitoring Extn
6th Mar 202311:00 amRNSPrice Monitoring Extension
25th Jan 202312:09 pmRNSHolding in Company
23rd Jan 20237:00 amRNSHalf-year Report
16th Jan 20237:00 amRNSAppointment of General Counsel & Notice of Results
12th Jan 20237:00 amRNSUpdate on combined Clinical Trial Application
5th Jan 202310:46 amRNSSubmission of combined Clinical Trial Application
4th Jan 20232:05 pmRNSSecond Price Monitoring Extn
4th Jan 20232:00 pmRNSPrice Monitoring Extension
4th Jan 202311:05 amRNSSecond Price Monitoring Extn
4th Jan 202311:00 amRNSPrice Monitoring Extension
3rd Jan 202311:05 amRNSSecond Price Monitoring Extn
3rd Jan 202311:00 amRNSPrice Monitoring Extension
29th Dec 20224:40 pmRNSSecond Price Monitoring Extn
29th Dec 20224:35 pmRNSPrice Monitoring Extension
15th Dec 20222:42 pmRNSDirector/PDMR Shareholding
15th Dec 202212:31 pmEQSProactive research analyst John Savin on Oxford Cannabinoid Technologies
15th Dec 20229:37 amEQSOxford Cannabinoid Technologies 'very confident' heading into 2023
12th Dec 20227:00 amRNSTrading Update
5th Dec 20222:39 pmEQSOxford Cannabinoid Technologies appoints new CEO
5th Dec 20227:00 amRNSDirectorate Change
15th Nov 20223:23 pmEQSOxford Cannabinoid Technologies nearly ready for new phase 1 trial
15th Nov 202211:28 amRNSHolding(s) in Company
11th Nov 202211:05 amRNSSecond Price Monitoring Extn
11th Nov 202211:00 amRNSPrice Monitoring Extension
17th Oct 20227:00 amRNSDirectorate Change
17th Oct 20227:00 amRNSDirectorate Change
28th Sep 20221:04 pmRNSResult of AGM
28th Sep 20227:00 amRNSAppointment of finnCap Ltd. as Corporate Broker
31st Aug 20227:00 amRNSNotice of AGM
26th Aug 20227:00 amRNSStrategic Budget Review & Directorate Change
15th Aug 20227:00 amRNSInaugural Meeting of Scientific Advisory Board
4th Aug 20227:00 amRNSFiling of 2022 Annual Report & Accounts
3rd Aug 202211:05 amRNSSecond Price Monitoring Extn
3rd Aug 202211:00 amRNSPrice Monitoring Extension
25th Jul 20227:00 amRNS2022 Final Results
20th Jul 20227:00 amRNSNotice of Results
20th Jul 20227:00 amRNSMSA and Work Order with Simbec Research
29th Jun 20227:00 amRNSTrading Update
30th May 20224:40 pmRNSSecond Price Monitoring Extn
30th May 20224:35 pmRNSPrice Monitoring Extension
16th May 20227:00 amRNSNew Broker and Investor Presentation
25th Apr 20227:00 amRNSFormation of Scientific Advisory Board
6th Apr 202212:58 pmRNSResults of Requisitioned General Meeting
1st Apr 20227:00 amRNSRegistered Office Address Change
31st Mar 20227:00 amRNSUpdates on Lead Programme 1 and Programme 2
11th Mar 202210:00 amRNSPosting of Circular & Notice of GM
10th Mar 202211:34 amRNSHolding in Company
8th Mar 20228:28 pmEQSData from pre-clinical study of OCT461201 shows positive results
8th Mar 20227:00 amRNSData from pre-clinical study show positive results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.